How to Buy Cytokinetics Stock
Cytokinetics Inc
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
Cytokinetics stock last closed at $56.18, up 1.89% from the previous day, and has decreased 9.68% in one year. It has overperformed other stocks in the Biotechnology industry by 0.87 percentage points. Cytokinetics stock is currently +4.91% from its 52-week low of $53.55, and -36.38% from its 52-week high of $88.31.
There are currently 139.3M CYTK shares outstanding. The market capitalization of CYTK is $7.83B. In the last 24 hours, 2.36M CYTK shares were traded.
How to Buy Cytokinetics Stock
Not sure how to invest in Cytokinetics stock? Here's how.
- Choose where to buy Cytokinetics stock: You need to choose an online brokerage, but don't worry - we've analyzed dozens of stock brokerages and apps to help you determine where to buy Cytokinetics stock.
- Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit funds into your brokerage account: Choose your method of payment and add your details.
- Research Cytokinetics stock: The Cytokinetics ticker symbol is CYTK. Is Cytokinetics stock a good investment? Should you buy shares of CYTK? How do CYTK's underlying business fundamentals look? Do top analysts think Cytokinetics is a good buy? Why has CYTK's stock price moved recently? (Hint: Our stock analysis website can help you figure out if CYTK is a good stock to buy).
- Place your CYTK trade: Decide if you will purchase CYTK shares at the current market price or use a limit order to purchase CYTK stock at a specific price.
- Keep an eye on your CYTK investment: Create a watchlist to track your position in Cytokinetics stock.
Step 1: Choose where to buy Cytokinetics stock
You need a brokerage account to access the NASDAQ market and buy CYTK shares.
Our recommended brokerage: eToro
Based on our research, eToro is the best place to buy stocks. Here's why:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world markets: From Tech to Utilities, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've chosen the best brokerage, the next step is to fill out some personal info so you are able to invest in CYTK stock today.
How to Set Up a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to open your new trading account.
- Send your details by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you have created your account on the best stock trading app, you need to deposit funds:
Check out the walkthrough below for more details transferring funds into your new investment account.
Step 4: Research Cytokinetics stock
After you have identified the best place to buy Cytokinetics stock, it's important to analyze their stock prior to investing, so you can comprehend the risk and opportunity.
Cytokinetics Numbers
CYTK Due Diligence Score
WallStreetZen was created to help average investors do better fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on CYTK's stock page.
Is CYTK stock undervalued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge CYTK's fair value.
You can access more valuation research on CYTK's stock here.
Is CYTK a healthy company?
Passed Financial Due Diligence Checks:
- CYTK has $1.13B in cash and short term investments. This is sufficient to cover its annual cash burn of $588.58M.
- There are more short-term assets than short-term liabilities on the CYTK balance sheet.
- CYTK has cash burn of 588577000. It has enough cash and short-term investments to cover this for at least one year.
Failed Financial Due Diligence Checks:
- There are more long-term liabilities than short-term assets on the CYTK balance sheet.
- Total CYTK debt is still negative.
- CYTK debt to equity ratio of -6.68 is negative.
- CYTK profit margin has gone up by 1.76 percentage points in the past year, but the company is still unprofitable.
Is it a good time to buy Cytokinetics stock, according to Wall Street analysts?
Out of 12 sell side analysts who track CYTK, the consensus analyst rating on Cytokinetics is a Strong Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
Most Recent CYTK Analyst Forecasts
Emily Field, a top 34% analyst from Barclays maintains CYTK with a strong buy rating and raises their CYTK price target from $95.00 to $110.00, on Aug 13, 2026.
Tessa Romero, a top 16% analyst from JP Morgan maintains CYTK with a strong buy rating and raises their CYTK price target from $97.00 to $103.00, on Aug 13, 2026.
JP Morgan's Tessa Romero raised their price target on Cytokinetics (NASDAQ: CYTK) by 6.2% from $97 to $103 on 2026/08/13. The analyst maintained their Strong Buy rating on the stock.
Cytokinetics reported its Q2 2026 earnings.
Following an assessment of the print, Romero said they raised their near-term projections for Myqorzo.*
Footnotes
* Myqorzo is a prescription medication approved in 2025/12 for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Earnings Report
For Q2 2026, Cytokinetics reported:
- EPS of $(1.50), which beat the Zacks Consensus Estimate of $(1.63) but missed Q2 2025's $(1.12).
- Revenue of $28.62M, which beat the Zacks Consensus Estimate by 40.2% but missed Q2 2025's $66.77M.
Management did not provide revenue or earning guidance in its press release.
President & CEO Robert I. Blum commented: “Our second quarter results demonstrate commercial launch momentum for MYQORZO alongside continued excellence for our development pipeline, both hallmarks of continued strong execution for our maturing business.
"In the U.S., we continued to build launch velocity evidenced by expanding physician adoption and increasing patient access.
"Internationally, we launched MYQORZO in Germany and laid the foundation for broadening access to aficamten by submitting reimbursement dossiers alongside regulatory filings advancing in multiple countries in Europe.
“We look forward to sharing results from ACACIA-HCM later this month and submitting a supplemental NDA to the U.S. Food and Drug Administration in the fourth quarter.
"Having also secured additional capital during the recent quarter, we have the financial resources to invest in both the global commercialization of MYQORZO and the continued progression of our pipeline, positioning us well to maximize the potential of our specialty cardiology franchise.”
Srikripa Devarakonda, a top 8% analyst from Truist Securities maintains CYTK with a strong buy rating and raises their CYTK price target from $106.00 to $112.00, on Aug 10, 2026.
Jason N. Butler, a bottom 5% analyst from Citizens maintains CYTK with a buy rating and raises their CYTK price target from $105.00 to $110.00, on Aug 7, 2026.
Serge Belanger, a top 2% analyst from Needham maintains CYTK with a buy rating and raises their CYTK price target from $102.00 to $112.00, on Aug 7, 2026.
You can dive deeper into what analysts are forecasting on the Cytokinetics stock forecast page.
CYTK Trading Indicators
CYTK Earnings
Last year, CYTK revenue was $113.29M. During the last five year, CYTK's revenue has gone up by 39.36% per year. This was faster than the Biotechnology industry average of 28.52%.
You can research CYTK's earnings and revenue performance here.
Are CYTK insiders buying or selling the stock?
Over the last year, insiders at CYTK have sold more shares than they have bought.
Fady Ibraham Malik, EVP of CYTK, was the latest CYTK insider to buy. They bought $27,300.00 worth of CYTK shares on Nov 3, 2026.
Dig into more about who owns CYTK shares here.
Does CYTK stock generate passive income?
No, Cytokinetics doesn't provide an income stream by paying out dividends.
CYTK Social Trading Data
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Place your CYTK trade
There are two primary options:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are usually sufficient. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a given price limit, use a limit order.
Hit the Open Trade button and eToro will place the order.
If you require additional info about buying stocks on eToro, click the helpful video below:
Step 6: Keep an eye on your CYTK investment
Now that you own some CYTK shares, you'll want to stay up-to-date on your investment.
Create a watchlist to see the latest developments about your CYTK stock.
CYTK Feed
How to Buy Stock in Cytokinetics
To reiterate, here are the 6 steps for buying Cytokinetics stock:
- Choose where to buy Cytokinetics stock
- Open your brokerage account
- Deposit funds into your brokerage account
- Research Cytokinetics stock
- Place your CYTK trade
- Keep an eye on your CYTK investment
If you need a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you want to keep track of your investment in Cytokinetics, create a watchlist today.
Other Content You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.